We demonstrate that while CLTCH129>Q-specific TCR 3 has a comparatively lower avidity for peptide–MHC complexes than TCR 1, CD4+ T cells expressing either TCR are similarly able to transduce TCR signaling, proliferate in vivo, contribute to CD8+ T cell- and CD40L-dependent primary tumor immunity and provide therapeutic tumor control. Here, CD40LG is linked to neoplasm.